Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
April 19, 2019
Does IP chemotherapy plus bevacizumab improves progression-free survival in women with optimally debulked ovarian cancer?
Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IV q3wks x6 cycles
bevacizumab 15 mg/kg IV starting cycle 2 + maintenance
(1) Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IP q3wks x6 cycles
bevacizumab 15 mg/kg IV starting cycle 2 + maintenance
(2) Paclitaxel 135 mg/m2 IV day 1 + cisplatin 75 mg/m2 IP day 2 + paclitaxel 60 mg/m2 IP day 8 q3wks x6 cycles
bevacizumab 15 mg/kg IV starting cycle 2 + maintenance
PFS
stage II - IV epithelial ovarian cancer
IP Carboplatin vs IP Cisplatin vs IV Carboplatin:
median f/u: 84.4 mos
median PFS: 27.4 vs 26.2 vs 24.9 months (NS)
median OS: 78.9 vs 72.9 vs 75.5 months (NS)
G3 adverse events: 17.2% vs 17.7% vs 11.5% (SS)
G3 HTN: 14% vs 20.5% vs 12%
G3 N/V: 5% va 11% vs 5%
No increases in bowel complications with IP chemo
PFS was not increased with either IP cisplatin or IP carboplatin regimens when combined with bevacizumab as compared with IV carboplatin with bevacizumab for optimally debulked ovarian cancer.